HepBest, containing Tenofovir Alafenamide (TAF), represents a leading-edge advancement in antiviral therapy, particularly for chronic Hepatitis B (HBV) and HIV-1 infection. It harnesses the power of TAF—an optimized prodrug of tenofovir—to deliver high intracellular drug concentrations with minimal systemic exposure. Consequently, HepBest maintains the exceptional efficacy of tenofovir while significantly reducing the risks associated with kidney and bone toxicity. Its presence in globally recognized fixed-dose combination regimens and once-daily monotherapy formats has shifted treatment standards, offering patients a highly effective yet safer antiviral therapy.